Imbruvica (ibrutinib) – New risk minimisation measures
03/11/2022
Medicines for human use
Direct healthcare professional communication (DHPC)
Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to the
increased risk for serious cardiac events.